RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors
January 04 2022 - 3:05PM
(NASDAQ: RXST) RxSight, Inc., an ophthalmic
medical device company dedicated to improving the vision of
patients following cataract surgery, today announced the
appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to
its Board of Directors.
“We are very excited to continue to strengthen the RxSight Board
of Directors with the additions of Dr. Fountain and Ms. Maniar.
Their diverse healthcare leadership experience will support the
strategic advancement of the company through its next chapter of
growth,” said J. Andy Corley, Chair of the Board of Directors. “We
look forward to their respective contributions as the RxSight®
Light Adjustable Lens system provides more doctors and patients the
ability to customize and optimize their vision following cataract
surgery.”
Dr. Fountain is a practicing ophthalmologist who served as the
2021 President of the American Academy of Ophthalmology and was
named to the board of directors of the American Board of
Ophthalmology in January 2022. She has been on faculty at Rush
University Medical Center in Chicago since May 1998 where she is
professor of ophthalmology and section chair emeritus of ophthalmic
plastic and reconstructive surgery. Dr. Fountain was chair for
Alumni Fund Giving at Harvard Medical School from January 2016 to
June 2019 and served as President of the American Society of
Ophthalmic Plastic and Reconstructive Surgery in 2018. She served
15 years on the board of directors of Ophthalmic Mutual Insurance
Company (OMIC), the largest, by market share, professional
liability insurer of ophthalmologists in the United States. At the
end of her term, Dr. Fountain was elected OMIC’s first woman chair
of the Board and chair of the Audit Committee, serving January 2014
to December 2015. She was President of the Illinois Society of Eye
Physicians and Surgeons January 2002 to December 2005. Dr. Fountain
received her B.A. in Human Biology from Stanford University, her
M.D. from Harvard Medical School, and completed her residency in
ophthalmology at Johns Hopkins Hospital’s Wilmer Eye Institute.
Ms. Maniar has served as Global Leader, Healthcare & Life
Sciences Solutions, Google Cloud - BioPharma at Google, where she
leads vision, strategy, and execution of Google Cloud's industry
product strategy and go-to-market model. Prior to joining Google,
from November 2013 to June 2018, she contributed as an executive at
Genentech, where she led market growth strategies relevant to
technology accelerators for therapies and diagnostics. For more
than a year previously, Ms. Maniar served as Director for the
Center of Minimally Invasive Therapeutics at Summa Health. Earlier
in her career, Ms. Maniar spent several years in a research
capacity at the Cleveland Clinic and the Austen BioInnovation
Institute in Akron, where she was primarily focused on medical
devices and minimally invasive therapeutics. She currently serves
on the board of directors of SeaSpine Holdings Corporation and is a
member of the Compensation Committee. Ms. Maniar holds a B.A. in
Economics from the University of California, San Diego.
About RxSight, Inc.RxSight, Inc. is a
commercial-stage medical technology company dedicated to improving
the vision of patients following cataract surgery. The RxSight®
Light Adjustable Lens system, comprised of the RxSight Light
Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD™) and
accessories, is the first and only commercially available
intraocular lens (IOL) technology that enables doctors to customize
and optimize visual acuity for patients after cataract surgery. The
LAL now features ActivShield™ technology, a revolutionary UV
protection layer built into the lens. Additional information about
RxSight can be found at www.rxsight.com.
Forward-Looking StatementsThis press release
contains “forward-looking statements,” including improving patient
vision after cataract surgery, with respect to the new board
members providing a future strategic role to the growth of RxSight,
the growth of RxSight and the ability of the RxSight Light
Adjustable Lens system providing doctors and patients the ability
to customize and optimize vision following cataract surgery.
Forward-looking statements are subject to known and unknown risks
and uncertainties, many of which may be beyond our control. We
caution you that the forward-looking information presented in this
press release is not a guarantee of future events, and that actual
events may differ materially from those made in or suggested by the
forward-looking information contained in this press release. In
addition, forward-looking statements generally can be identified by
the use of forward-looking terminology such as “may,” “plan,”
“seek,” “will,” “expect,” “intend,” “estimate,” “anticipate,”
“believe” or “continue” or the negative thereof or variations
thereon or similar terminology. Any forward-looking information
presented herein is made only as of the date of this press release,
and we do not undertake any obligation to update or revise any
forward-looking information to reflect changes in assumptions, the
occurrence of unanticipated events, or otherwise.
Investor contact:Philip Taylor Gilmartin
Group415.937.5406IR@rxsight.com
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jun 2024 to Jul 2024
RxSight (NASDAQ:RXST)
Historical Stock Chart
From Jul 2023 to Jul 2024